- Opinion
- [Reporter's view]Double regulation of penalties for rebates
- by Lee, Jeong-Hwan Nov 2, 2020 06:12am
- Rebates in the Pharmaceutical Industry's trick to `ship to pharmacies' has been repeated for decades. Some of them are established as practice and are taken for granted. During the two-week grace period given by the MFDS prior to the suspension of sale, pharmaceutical companies are actually making total sales by releasing drugs that cannot
- Policy
- Vildagliptin generic preferential sales date may get delayed
- by Lee, Tak-Sun Oct 30, 2020 05:55am
- The preferential sales rights Ahn-gook Pharmaceutical has earned for the Galvus (vildagliptin) generic could be cut as a higher court trial has overturned the patent litigation decision. Accordingly, the South Korea’s Ministry of Food and Drug Safety (MFDS) is internally reviewing the matter. On Oct. 29, the Patent Court has partially r
- Policy
- Roche approved to release a new drug treating lymphoma
- by Lee, Tak-Sun Oct 30, 2020 05:55am
- A new drug by Roche, Polivy injection (polatuzumab vedotin), is released to the South Korean market to treat patients with lymphoma, a type of blood cancer. The injection, used in combination with bendamustine and rituximab, is expected to be a new option for patients not responsive to the existing treatment. On Oct. 27, the Ministry
- Policy
- Can the ICER value increase the range of GDP?
- by Kim, Jung-Ju Oct 30, 2020 05:55am
- The National Assembly is calling for an increase in the incremental cost effectiveness ratio (ICER), which is used as the basis for price determination, for reimbursement of expensive drugs, which is the key to strengthening the coverage of Moon Jae In Care pharmaceutical sector. This is because the price of breakthrough new drugs used for se
- Company
- Boryung recorded the largest quarterly sales performance
- by An, Kyung-Jin Oct 30, 2020 05:54am
- Boryung's quarterly performance improved even amid the economic downturn caused by COVID-19. The growth of new drugs introduced by multinational pharmaceutical companies, centering on Kanarb Family developed with their own technology, has contributed to the improvement of the performance of the Prescription drugs division. Boryung announc
- Company
- Novartis "No more order suspension for Myfortic 3rd trial"
- by Kim, Jin-Gu Oct 30, 2020 05:54am
- Although Novatis took an appeal case on the pricing reduction order for Myfortic Enteric Coated Tablet to the Supreme Court, the company has reportedly decided to not request to halt the administration order. Even if the South Korea’s Ministry of Health and Welfare (MOHW) issues an order to bring down the drug pricing according to the se
- Company
- Interview: More options in CDK4/6 inhibitor-Faslodex
- by Eo, Yun-Ho Oct 29, 2020 05:52am
- The emergence of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in treatment of patients with human epidermal growth factor receptor 2-negative (HER2-) breast cancer has brought a change in treatment pattern. Technically, chemotherapy was the only option in the hormone receptor-positive (HR+) and HER2- breast cancer. Ibrance (palbocic
- Policy
- Pantoprazole, shouldn’t be exceed 20mg per day
- by Lee, Tak-Sun Oct 29, 2020 05:52am
- For Pantoprazole, one of the anti-ulcer PPI, the MFDS is pursuing a change in the approval so that it does not exceed 20 mg per day for patients with severe hepatic impairment. Previously, it was supposed to take 40mg once every other day, but it was not to exceed 20mg per day. The MFDS recently prepared a proposal for amendment of the
- Policy
- The MFDS begins preliminary screening for COVID-19 vaccine
- by Lee, Tak-Sun Oct 29, 2020 05:52am
- It was revealed that the domestic health authorities have begun a preliminary review of the COVID-19 vaccine that AstraZeneca is developing. It is explained that applications for domestic approval are expected after three months as soon as possible. Among vaccines currently being developed at home and abroad, it is the fastest for domesti
- Company
- MSD has appointed So-eun Kim as the first CEO of Organon
- by Oct 29, 2020 05:51am
- MSD announced on the 27th that it has appointed So-eun Kim (49 years old), currently managing director of MSD Korea, as the new CEO of Organon & Co, which will be newly established through the spin-off in the first half of 2021. Organon & Co's term of office begins on February 1, 2021, when the division of the company in Korea is complete
